07:00 , Aug 6, 2012 |  BioCentury  |  Emerging Company Profile

Ascletis: Cash for China deals

While Ascletis Pharmaceuticals Co. Ltd. aspires to discover its own drugs, it is employing a two-pronged strategy that includes in-licensing clinical candidates for the Chinese market. Its first external compound comes from Alnylam Pharmaceuticals Inc. According...